Meeting
2023 ASCO Quality Care Symposium
Disparities in clinical trial participation beyond first-line treatment among patients with metastatic breast or colorectal cancer.
Authors
Jennifer S. Wang
University of Texas Health Science Center at Houston, Houston, TX
Jennifer S. Wang, Benny Johnson, Carlos Hernando Barcenas, Andrea Betts, Caitlin C. Murphy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Access to Clinical Trials
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 97)
DOI
10.1200/OP.2023.19.11_suppl.97
Abstract #
97
Poster Bd #
B4
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Continued cetuximab in second-line treatment for patients with unresectable metastatic wild-type KRAS, NRAS, and BRAF colorectal cancer after disease progression during first-line cetuximab-based therapy.
First Author: Ying Liu
Poster
2024 ASCO Breakthrough
Real-world outcomes with lurbinectedin in second-line and beyond for small cell lung cancer in Korea.
First Author: Joosung Gabriel Shim
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Are adverse events (AEs) during first-line FOLFIRINOX (FFX) more frequent in real-world (RW) patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who do not proceed to second-line therapy?
First Author: Ravi Kumar Paluri
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line.
First Author: Syvart Dennen